COFETUZUMAB PELIDOTIN

Cofetuzumab pelidotin is an antibody drug conjugate pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

3 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

No data

Indications Phases 2

No data

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neoplasms	D009369	—	C80	2	—	—	—	—	2
Non-small-cell lung carcinoma	D002289	—	—	1	—	—	—	—	1
Lung neoplasms	D008175	HP_0100526	C34.90	1	—	—	—	—	1
Breast neoplasms	D001943	EFO_0003869	C50	1	—	—	—	—	1
Triple negative breast neoplasms	D064726	—	—	1	—	—	—	—	1

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	COFETUZUMAB PELIDOTIN
INN	cofetuzumab pelidotin
Description	Cofetuzumab pelidotin (INN; development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.
Classification	Antibody
Drug class	synthetic analogs of the dolastatin series; monoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—